Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 13/20 | 0.72 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27391448 | 0.88 | PYCR1 (0.72) | PYCR1MAOBHDAC6HDAC1HDAC8 | |
| SCHEMBL10033801 | 0.83 | PYCR1 (0.79) | PYCR1MAOBACHELMNAUSP2 | |
| SCHEMBL28696676 | 0.81 | HDAC6 (0.60) | PYCR1HDAC6HDAC1HDAC8 | |
| SCHEMBL28690762 | 0.79 | HDAC1 (0.61) | PYCR1HDAC6HDAC1HDAC8 | |
| SCHEMBL610818 | 0.78 | PYCR1 (0.60) | PYCR1MAOBHDAC6HDAC1HDAC8 | |
| SCHEMBL28697641 | 0.78 | HDAC6 (0.56) | PYCR1HDAC6HDAC1HDAC8 | |
| SCHEMBL28690802 | 0.78 | HDAC6 (0.56) | PYCR1HDAC6HDAC1HDAC8 | |
| SCHEMBL13261470 | 0.78 | HDAC6 (0.64) | HDAC6HDAC1HDAC8 | |
| SCHEMBL28699833 | 0.78 | CA1 (0.59) | PYCR1MAOBHDAC6HDAC1HDAC8 | |
| SCHEMBL611531 | 0.77 | MAOB (0.59) | MAOBHDAC6HDAC1HDAC8ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802675-B2 | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2014-08-12 | — | — | US | disclosed |
| US-8802675-B2 | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2014-08-12 | — | — | US | disclosed |
| US-8802675-B2 | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2014-08-12 | — | — | US | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
| WO-2010086860-A2 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | GSR, GRIN1, GRIN2A | PYCR1 426/4885MAOB 12/4885HDAC6 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.